Neurological manifestations of COVID-19 and other coronaviruses: A systematic review.
Neurol Psychiatry Brain Res
; 37: 27-32, 2020 Sep.
Article
em En
| MEDLINE
| ID: mdl-32834527
ABSTRACT
OBJECTIVE:
To describe the main neurological manifestations related to coronavirus infection in humans.METHODOLOGY:
A systematic review was conducted regarding clinical studies on cases that had neurological manifestations associated with COVID-19 and other coronaviruses. The search was carried out in the electronic databases PubMed, Scopus, Embase, and LILACS with the following keywords "coronavirus" or "Sars-CoV-2" or "COVID-19" and "neurologic manifestations" or "neurological symptoms" or "meningitis" or "encephalitis" or "encephalopathy," following the Systematic Reviews and Meta-Analyses (PRISMA) guidelines.RESULTS:
Seven studies were included. Neurological alterations after CoV infection may vary from 17.3% to 36.4% and, in the pediatric age range, encephalitis may be as frequent as respiratory disorders, affecting 11 % and 12 % of patients, respectively. The Investigation included 409 patients diagnosed with CoV infection who presented neurological symptoms, with median age range varying from 3 to 62 years. The main neurological alterations were headache (69; 16.8 %), dizziness (57, 13.9 %), altered consciousness (46; 11.2 %), vomiting (26; 6.3 %), epileptic crises (7; 1.7 %), neuralgia (5; 1.2 %), and ataxia (3; 0.7 %). The main presumed diagnoses were acute viral meningitis/encephalitis in 25 (6.1 %) patients, hypoxic encephalopathy in 23 (5.6 %) patients, acute cerebrovascular disease in 6 (1.4 %) patients, 1 (0.2 %) patient with possible acute disseminated encephalomyelitis, 1 (0.2 %) patient with acute necrotizing hemorrhagic encephalopathy, and 2 (1.4 %) patients with CoV related to Guillain-Barré syndrome.CONCLUSION:
Coronaviruses have important neurotropic potential and they cause neurological alterations that range from mild to severe. The main neurological manifestations found were headache, dizziness and altered consciousness.
ACE2, angiotensin converting enzyme 2; ADEM, acute disseminated encephalomyelitis; ANHE, acute necrotizing hemorrhagic encephalopathy; BBE, Bickerstaff's encephalitis; COVID-19; COVID-19, coronavirus disease 2019; CoV, coronavirus; Coronavirus; DPP4, dipeptidil peptidase 4; Encephalopathy; G-CSF, granulocyte colony stimulating factor (G-CSF); GBS, Guillain-Barré syndrome; GM-CSF, granulocyte-macrophage colony-stimulating factor; HCoV, Humanâ¯coronavirus; HCoV-229E, Human coronavirus 229E; HCoV-OC43, Human coronavirus OC43; ICU, intensive care unit; IL, interleukin; MCP-1, monocyte chemoattractant protein-1; MERS, Middle East respiratory syndrome; MERS-CoV, Middle East respiratory syndrome coronavirus; Neurologic manifestations; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; SARS, severe acute respiratory syndrome; SARS-CoV-2; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SARSCoV, severe acute respiratory syndrome coronavirus; ßCoV, betacoronavírus
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Guideline
/
Systematic_reviews
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article